Literature DB >> 8456437

Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis.

G Dickneite1, E P Pâques.   

Abstract

Experimental gram-negative sepsis was induced in the rat by Klebsiella pneumoniae. Although bacteria are susceptible to the treatment with the antibiotic Tobramycin, DIC could not be prevented. DIC was manifested by a leuko- and thrombocytopenia, decreases in fibrinogen and AT III and an increase of the aPTT. In this model the therapeutic treatment with human AT III was evaluated. To determine the optimal concentration of AT III a prestudy in a LPS induced DIC in the rat was performed. It was shown that a bolus i.v. injection of 500 U/kg improved survival and DIC, and was thus chosen for the Klebsiella sepsis model. The infectious load was adjusted to yield a mortality rate of 90-100% in the untreated Klebsiella group and a reduction to about 40-50% of the mortality rate by Tobramycin. It was found that AT III reduced mortality in the Klebsiella induced sepsis not only when given prophylactically but was effective even when administrated in a late stage of the DIC, i.e. 3 or 5 h post infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8456437

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  11 in total

Review 1.  [Microcirculation and hemostasis in inflammatory processes. Modulation by administration of physiologic protease inhibitors as a therapeutic approach].

Authors:  B Leithäuser; F R Matthias
Journal:  Med Klin (Munich)       Date:  1997-07-15

2.  Activation of Syk by protein kinase C-delta regulates thrombin-induced intercellular adhesion molecule-1 expression in endothelial cells via tyrosine phosphorylation of RelA/p65.

Authors:  Kaiser M Bijli; Fabeha Fazal; Mohd Minhajuddin; Arshad Rahman
Journal:  J Biol Chem       Date:  2008-03-24       Impact factor: 5.157

3.  Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.

Authors:  F Baudo; T M Caimi; F de Cataldo; A Ravizza; S Arlati; G Casella; D Carugo; G Palareti; C Legnani; L Ridolfi; R Rossi; A D'Angelo; L Crippa; D Giudici; G Gallioli; A Wolfler; G Calori
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

4.  Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis.

Authors:  H Yamaguchi; H Weidenbach; H Lührs; M M Lerch; G Dickneite; G Adler
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

5.  Protein kinase C-delta and phosphatidylinositol 3-kinase/Akt activate mammalian target of rapamycin to modulate NF-kappaB activation and intercellular adhesion molecule-1 (ICAM-1) expression in endothelial cells.

Authors:  Mohd Minhajuddin; Kaiser M Bijli; Fabeha Fazal; Antonella Sassano; Keiichi I Nakayama; Nissim Hay; Leonidas C Platanias; Arshad Rahman
Journal:  J Biol Chem       Date:  2008-12-13       Impact factor: 5.157

6.  Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.

Authors:  B Eisele; M Lamy; L G Thijs; H O Keinecke; H P Schuster; F R Matthias; F Fourrier; H Heinrichs; U Delvos
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

7.  Regulation of Rela/p65 and endothelial cell inflammation by proline-rich tyrosine kinase 2.

Authors:  Kaiser M Bijli; Fabeha Fazal; Arshad Rahman
Journal:  Am J Respir Cell Mol Biol       Date:  2012-07-27       Impact factor: 6.914

8.  The anti-inflammatory action of Bothrops jararaca snake antithrombin on acute inflammation induced by carrageenan in mice.

Authors:  Karen de Morais-Zani; Fernanda Peixoto Barbosa Nunes; Jacilene Barbosa da Silva; Márcio José Ferreira; Kathleen Fernandes Grego; Mônica Lopes-Ferreira; Aparecida Sadae Tanaka; Anita Mitico Tanaka-Azevedo
Journal:  Inflamm Res       Date:  2013-05-12       Impact factor: 4.575

Review 9.  Coagulation inhibitor substitution during sepsis.

Authors:  F Fourrier; M Jourdain; A Tournois; C Caron; J Goudemand; C Chopin
Journal:  Intensive Care Med       Date:  1995-11       Impact factor: 17.440

Review 10.  Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis.

Authors:  Christian J Wiedermann
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.